Outcomes related to FDG-PET-CT response in patients with Hodgkin Lymphoma treated with brentuximab-vedotin at relapse or consolidation
: Brentuximab-vedotin (BV) monotherapy has shown high efficacy in heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma (HL) after high-dose chemotherapy or autologous stem cell transplantation (ASCT). We retrospectively analyzed the outcomes of treatment with BV of HL patients and examined the predictive ability of PET-CT for response in this setting.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Meirav Kedmi, Pavel Khaustov, Elena Ribakovsy, Ohad Benjamini, Abraham Avigdor Source Type: research
More News: Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Transplants